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Background: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by
numerous fluid-filled cysts that frequently result in end-stage renal disease. While promising treatment options are
in advanced clinical development, early diagnosis and follow-up remain a major challenge. We therefore evaluated
the diagnostic value of Fetuin-A as a new biomarker of ADPKD in human urine.
Results: We found that renal Fetuin-A levels are upregulated in both Pkd1 and Bicc1 mouse models of ADPKD.
Measurement by ELISA revealed that urinary Fetuin-A levels were significantly higher in 66 ADPKD patients
(17.5 ± 12.5 μg/mmol creatinine) compared to 17 healthy volunteers (8.5 ± 3.8 μg/mmol creatinine) or 50 control
patients with renal diseases of other causes (6.2 ± 2.9 μg/mmol creatinine). Receiver operating characteristics (ROC)
analysis of urinary Fetuin-A levels for ADPKD rendered an optimum cut-off value of 12.2 μg/mmol creatinine,
corresponding to 94% of sensitivity and 60% of specificity (area under the curve 0.74 ; p = 0.0019). Furthermore,
urinary Fetuin-A levels in ADPKD patients correlated with the degree of renal insufficiency and showed a significant
increase in patients with preserved renal function followed for two years.
Conclusions: Our findings establish urinary Fetuin-A as a sensitive biomarker of the progression of ADPKD. Further
studies are required to examine the pathogenic mechanisms of elevated renal and urinary Fetuin-A in ADPKD.
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Autosomal dominant polycystic kidney disease (ADPKD)
is the most common inherited kidney disease, affecting
as many as 1 in 1000 individuals world-wide, but with
variable course and prognosis [1-3]. It is caused by mu-
tations in the polycystic kidney disease (PKD)-1 or less
frequently in the PKD2 gene [4-7]. ADPKD is character-
ized by the progressive development of numerous large
fluid-filled cysts especially in the kidneys over a period
of decades [8]. Cystic growth results in dramatic kidney
enlargement, and it induces reactive interstitial inflam-
mation and fibrosis, leading frequently to end stage renal
disease (ESRD) [9]. However, important unresolved is-
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unless otherwise stated.In particular, what determines the rate of cyst progres-
sion in patients is unclear, and diagnostic tools to predict
disease outcome are elusive. Diagnosis is usually estab-
lished by renal imaging (ultrasonography, CT-scan or
MRI) when there is a positive family history [7]. How-
ever, cysts may only appear late in the course of the dis-
ease, creating a diagnostic gap. Direct genetic analysis is
feasible, but remains challenging owing to the large size,
complex genomic structure and allelic heterogeneity of
PKD1 and PKD2 genes [10,11]. Disease progression is
usually assessed by repeated analysis of plasma creatin-
ine levels as readout of glomerular filtration rates (GFR).
However, plasma creatinine levels only start rising when
the disease is already well advanced. To improve diagno-
sis and early follow-up of ADPKD, current efforts focus
on renal volume assessment by MRI or CT-scan and on
non-invasive urine biomarkers. Assessment of renal vol-
ume allows an earlier follow-up of the disease and the
management of associated symptoms such as hyperten-
sion [12]. Only few candidate biomarkers have beenl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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neutrophil gelatinase-associated lipocalin (NGAL) [15] and
monocyte chemotactic protein 1 (MCP-1) [16,17]. With the
notable exception of albuminuria [18,19], these remain to
be validated.
Future diagnostic and innovative therapeutic approa-
ches may be guided by insights from rodent models of
ADPKD with spontaneous or engineered mutations [20].
Among such models, mouse kidneys lacking Pkd1 are
arguably the most disease-relevant since human PKD1 is
mutated in 85% of ADPKD patients [21]. Interestingly,
conditional knockout of a targeted Pkd1 allele (Pkd1cKO)
in mouse kidneys before or after postnatal day 12–14 re-
vealed that the susceptibility to cystic growth dramatically
decreases after day 13, coincident with a metabolic switch
and a sudden decline of cell proliferation at this stage of
postnatal development [22-25]. Transcriptome profiling of
Pkd1cKO kidneys revealed that even the aggressive early-
onset disease is initiated independently of changes in gene
expression levels above 2-fold, and with less than 100
genes de-regulated [24]. Therefore, it may be difficult
to identify sensitive markers linked to the etiology of
ADPKD that are significantly deregulated at the tran-
scriptional level.
Renal cysts also develop in mice and humans carrying
mutations in the Bicc1 gene that encodes the cyto-
plasmic RNA-binding protein Bicaudal-C [26-29]. Bicc1
expression partly depends on Pkd1 [30] and in turn
stimulates the translation of Pkd2 mRNA [27], indicating
that Bicaudal-C mediates critical polycystin functions. A
candidate search for direct targets revealed that Bicc1
binds adenylate cyclase-6 (AC6) mRNA and reduces its
translation [27]. AC6 is likely a ADPKD-relevant target
as it contributes to cyst formation in Pkd1-deficient
mouse kidneys [31]. However, since AC6 or other known
direct Bicc1 targets cannot be monitored non-invasively,
we decided instead to initially screen for candidate bio-
markers using gene expression profiling.
Here, we report that polycystic mouse kidneys induced
by targeted deletion of Pkd1 or Bicc1 as well as the urine
of ADPKD patients contain elevated levels of Fetuin-A.
Fetuin-A (also known as α2-Heremans Schmid glycopro-
tein, AHSG, FETUA) is a multifunctional negative acute
phase protein in blood plasma that regulates insulin
signaling, bone resorption, and the precipitation of cal-
ciprotein particles [32]. During development, FETUA is
expressed in several tissues and organs, including the
brain, liver, bone, kidney, and respiratory and cardiovas-
cular systems [33], whereas in adults, its expression nor-
mally is restricted to the liver [34]. Despite the absence
of FETUA mRNA, the protein has been detected in prox-
imal tubule epithelial cells of adult rat kidneys by immu-
nostaining, and this staining can be inhibited by blocking
megalin-mediated endocytosis [35]. Thus, Fetuin-A mayenter proximal tubule cells by reabsorption from the
tubule lumen after passing from plasma through the
glomerular slit diaphragm [35,36]. We show that Bicc1
mutant cystic kidneys fail to retain the protein and instead
release it into urine. We show that urinary Fetuin-A levels
are also elevated in patients with ADPKD compared to
healthy volunteers. Our findings reveal a new trait shared
among ADPKD patients and the Bicc1 mouse model, and
they suggest that Fetuin-A is a promising new disease bio-
marker that should be considered for further prospective
studies and to investigate its potential role in ADPKD
pathogenesis.
Results
Upregulation of Fetuin-A in two mouse models of
polycystic kidney disease
Insights into disease pathogenesis and identification of
biomarkers may be accelerated by genome-wide tran-
scriptome analysis [37]. To this end, total RNA from 3
Bicc1KO embryos and 3 wild-type (WT) control litter-
mates was isolated shortly after the onset of cyst formation
and subjected to Affymetrix cDNA array hybridization.
Array analysis only revealed very few and modest changes
at the level of gene transcription (less than 70 genes being
changed more than 1.5-fold, data not shown). Among
these changes was a 3.5-fold upregulation of the FETUA
transcript (p = 0.006). Consistently, Western blot analysis
of renal extracts at E16.5 (i.e. during onset of cyst forma-
tion), P0 and P5 showed increasing expression of Fetuin-A
protein with the expected apparent molecular weight of
59 kDa in Bicc1KO compared to WT (Figure 1a). While
Fetuin-A is mainly synthesized in the liver after birth
[34], Western blot analysis of liver extracts at P1 and P3
revealed no difference in its expression in Bicc1KO
compared to the WT (Figure 1b). This result suggests
that Fetuin-A expression is increased in Bicc1KO kidneys,
rather than systemically.
To verify whether the increase in renal Fetuin-A was
related to cyst formation, we analyzed kidneys carrying a
conditional Pkd1 allele that was deleted by tamoxifen-
inducible KspCad-CreERT2 [23,25]. Compared to WT,
Fetuin-A was upregulated up to 2.7-fold (p < 0.001) during
an early stage of cyst formation, and 7.8-fold (p < 0.001) in
animals with advanced cysts (Figure 1c). These results sug-
gest a possible correlation between the level of Fetuin-A
and the progression of the disease.
Fetuin-A levels are low in cyst-lining cells, but increase in
urine of Bicc1KO mice
To obtain further insight into the regulation of Fetuin-A,
we examined its distribution in WT and Bicc1KO
newborn kidneys by immunostaining. Co-labeling with
Lotus tetragonolobus lectin, which specifically labels
proximal tubules [38] revealed Fetuin-A expression in
Figure 1 Expression of Fetuin-A in mouse models of polycystic kidney disease. (a, b) Western blot analysis of Fetuin-A in (a) kidney and (b)
liver extracts of the indicated genotypes. (c) Western blots of Fetuin-A in early stages of cyst formation (3 weeks, n = 4 for each genotype) or
advanced cystic kidneys (9 weeks, n = 4 for each genotype) of wild-type or KspCad-CreERT2; Pkd1fl/fl kidneys after tamoxifen administration at
postnatal days 10–12. Signal quantification by Image J is shown on the right after normalization to loading control (γ-tubulin). Error bars represent
standard deviation. n.s.: non-significant.
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(Figure 2a). Fetuin-A was neither detected in the medulla
nor in the renal pelvis (Additional file 1: Figure S1), con-
curring with data obtained in rat kidneys [35]. Paradoxic-
ally, despite the marked elevation of Fetuin-A in total
extracts of Bicc1KO newborn kidneys above WT control
(Figure 1a), immunolabelling only detected very sparse
Fetuin-A staining in few cyst-lining cells in proximal tu-
bules (Figure 2a). To assess whether Fetuin-A accumulates
in the urine, we collected urine samples from the bladder
at P0 or P3. Compared to heterozygous and WT litter
mates, urine from Bicc1KO showed an up to 60-fold in-
crease in Fetuin-A levels (n = 5/5, p < 0.005) (Figure 2b).
We conclude that cystic Bicc1KO kidneys enrich Fetuin-A
in the urine.
Levels of urinary Fetuin-A correlate with disease progression
in ADPKD patients
We therefore evaluated urinary Fetuin-A as a potential
ADPKD biomarker in humans. ELISA analysis was con-
ducted on urine samples from 66 ADPKD patients, 17
healthy volunteers and 50 patients with renal diseases of
other causes than ADPKD. Clinical characteristics and
laboratory variables of patients are reported in Table 1
and Additional file 2: Table S1. Urinary levels of Fetuin-
A normalized to creatinine were significantly higher in
ADPKD patients (17.5 ± 12. 9 μg/mmol creatinine) com-
pared to healthy volunteers (8.5 ± 3.8 μg/mmol creatin-
ine) and to patients with various renal diseases other
than ADPKD (6.2 ± 2.9 μg/mmol creatinine) (Figure 3a).
To verify the expression of urinary Fetuin-A in individ-
ual urine samples by Western blotting, 11 samples from
ADPKD patients and patients with various renal diseases
other than ADPKD were randomly selected. The result
demonstrated that urinary Fetuin-A levels were signifi-
cantly augmented in ADPKD group, correlating with the
ELISA analysis (Additional file 3: Figure S2). Moreover,
consecutive analysis in 6 months intervals during 2 years
in 19 patients with early-stage ADPKD (eGFR > 60 ml/
min/1.73 m2) showed that urinary excretion of Fetuin-A
increased progressively (p = 0.031, one-way ANOVA)
(Figure 3b, Additional file 4: Figure S3a and Table 2). By
contrast, eGFR did not significantly change over the
same time period (Additional file 4: Figure S3b). This
suggests that the levels of Fetuin-A in urine may be a
more sensitive marker in determining disease progres-
sion than eGFR. Consistently, a significant correlation
was found between chronic kidney disease (CKD) stages
and the levels of urinary Fetuin-A in ADPKD patients
(p = 0.024, one-way ANOVA) (Figure 3c, Additional file 4:
Figure S3c and Table 3). To further validate this conclu-
sion, we determined cut-off values discriminating ADPKD
patients from normal volunteers using Receiver Operating
Characteristics (ROC) curves (Figure 4). All areas underthe curves (AUC) were significantly different from chance.
Urinary Fetuin-A levels of advanced ADPKD (eGFR <
60 ml/min/1.73 m2) showed the highest AUC (0.87, p <
0.0001) and that Fetuin-A values at 12.2 μg/mmol creatin-
ine distinguished patients from healthy controls with 94%
of sensitivity and 74% of specificity. Fetuin-A values at
12.2 μg/mmol creatinine distinguished patients with early
ADPKD (eGFR > 60 ml/min/1.73 m2) from healthy con-
trols, but the sensitivity and specificity were 94% and 58%,
respectively. These analyses yielded optimum cut-off
values of 12.2 μg/mmol creatinine for the establishment of
ADPKD diagnosis with a high sensitivity and a reasonable
specificity.
Discussion
Improving early diagnosis and follow-up of ADPKD pa-
tients remains a major challenge, especially for disease
management in the new era of future therapeutic inter-
ventions [39]. Ongoing efforts so far have mainly focused
on imaging (CRISP consortium) [40] and on new disease
biomarkers [41-44]. However, despite intense efforts, the
development of non-invasive biomarkers is still in its
infancy. Here, we found that two independent mouse
models of ADPKD express elevated levels of Fetuin A in
the kidney, and that average urinary Fetuin-A levels in-
crease during disease progression in affected ADPKD
patients.
Renal Fetuin-A levels increased in the urine of
ADPKD patients compared to healthy volunteers, as well
as in urine and total kidney extracts of the non-
orthologous Bicc1−/− mouse model. In view of the posi-
tive data from urine of patients, we did not attempt to
extend our study to urine of conditionally Pkd1-deleted
mutant mice. Nevertheless, analysis of whole kidneys
confirmed that Fetuin-A is also upregulated in this
orthologous mouse model, in keeping with a role as a
disease-relevant marker. Importantly, the levels of urin-
ary Fetuin-A in ADPKD patients correlated with the
stage of renal insufficiency during disease progression.
In good agreement, Fetuin-A has also been detected
within ADPKD kidneys by mass spectrometry analysis of
cyst fluid [45]. Together, these observations indicate that
Fetuin-A is a sensitive biomarker of disease progression.
Fetuin-A initially attracted our attention because of an
apparent upregulation detected by microarray gene ex-
pression profiling of embryonic Bicc1KO kidneys already
at the early onset of cystic disease. However, local tran-
scriptional de-regulation within the kidney could not be
confirmed either by Taqman or SYBR Green qRT-PCR
due to low baseline expression and substantial variability
among samples both in wild-type and cystic newborn
kidneys (unpublished observation). Furthermore, immu-
nolabelling detected Fetuin-A in vesicles of wild-type
proximal tubules as described previously in the rat [35],
Figure 2 Localization and excretion of urinary Fetuin-A in newborn kidneys. (a) Frozen sections of WT (n = 2) and Bicc1KO newborn kidneys
(n = 4) labeled with anti-Fetuin-A antibody (green), and Lotus tetragonolobus lectin (LTL, red). Bicc1 heterozygotes (n = 2) were indistinguishable
from WT (not shown). Scale bars: 100 μm. (b) Western blot analysis of urinary Fetuin-A excretion of the indicated genotypes at stages P0 and P3.
Signal quantification by ImageJ is shown below. Error bars represent standard deviation.
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Table 1 Clinical characteristics and laboratory variables of patients subjected to ELISA analysis
Healthy
volunteers
Renal diseases other
than ADPKD
ADPKD
Total Early Advanced
Cases (n) 17 50 66 36 30
Age (Years)* 34.9 ± 11.1 65.3 ± 12.6 43.1 ± 17.2 31.9 ± 12.7 56.3 ± 11.5
Gender (n)**
• Male 53 (9) 66 (33) 48 (32) 50 (18) 47 (14)
• Female 47 (8) 34 (17) 52 (34) 50 (18) 53 (16)
Pathologies (n)**
• Diabetes - 20 (10) 3 (2) - 6 (2)
• Obesity (BMI > 30 kg/m2) - 16 (8) 3 (2) 3 (1) 3 (1)
• Hypercholesterolemia - 24 (12) 7 (5) - 16 (5)
eGFR [mL/min/1.73 m2]* N.A. 30.0 ± 15.1 71.8 ± 38.8 102.5 ± 20.6 35.4 ± 17.4
Proteinuria [g/ mmol creatinine]* N.A. 0.621 ± 0.06 0.139 ± 0.05 0.101 ± 0.04 0.215 ± 0.02
High BP, (n)** - 44 (22) 85 (56) 75 (27) 96 (29)
Fetuin-A (U) [μg/L]* 78.7 ± 39.5 39.2 ± 13.1 104.9 ± 58.7 89.1 ± 48.4 124.1 ± 64.7
Fetuin-A (U) [μg/mmol creatinine]* 8.5 ± 3.8 6.2 ± 2.9 17.5 ± 12.9 13.8 ± 9.6 21.8 ± 14.3
*Data are presented as mean ± SD. ADPKD, autosomal dominant polycystic kidney disease; eGFR, estimated glomerular filtration rate; N.A., not assessed; (U), urine.
**Values are in percentage. Absolute numbers are in brackets. High BP is defined as systolic BP >140 and/or diastolic BP >90 mmHg (mean of three measurements) or
the need for anti-hypertensive medication.
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than being increased. Nevertheless, the levels of Fetuin-
A detected by Western blot clearly increased in Bicc1KO
compared to wild-type, both in total kidney extracts and
in urine. Analysis of livers detected no systemic upregu-
lation or increased hepatic production. Moreover, in a
cohort of ADPKD patients that was followed during
24 months, we found that the levels of urinary Fetuin-A
significantly increased without a corresponding increase
in eGFR. Taken together, these findings suggest that
Fetuin-A specifically accumulates in the urine of cystic
kidneys, probably due to impaired renal reabsorption ra-
ther than increased filtration or secretion.
Fetuin-A is also secreted in the urine during advanced
diabetic nephropathy [46]. However, the levels of urinary
Fetuin-A in these patients correlate with microalbumi-
nuria, indicating that Fetuin-A leaked through defective
glomeruli and failed to be reabsorbed in proximal tu-
bules. Fetuinuria in diabetic nephropathy thus likely has
a different origin than in ADPKD. The levels of Fetuin-A
in urine also increase during acute kidney injury (AKI),
which can be induced by cisplatin or by ischemia-
reperfusion [47]. During AKI, Fetuin-A was enriched both
in the cytoplasm of damaged proximal tubule cells and in
urine [47], similar to what we observed in cystic kidneys
of Bicc1 KO mice. By contrast, we detected no upregula-
tion of Fetuin-A in the urine of patients with various renal
diseases other than ADPKD. Also in urine of patients with
kidney stones, a recent study reported a decrease inthe levels of Fetuin-A, rather than an increase [48]. Thus,
rather than being a general reaction to renal injury, ele-
vated Fetuin-A in adult human kidneys appears to be part
of a program that is linked to ADPKD.
Acknowledged limitations of this study include the
absence of kidney volume assessment for quantifying
the rate of disease progression, and that our patient
group has not been stratified by genotype or extrarenal
manifestations such as hypertension or liver cysts.
Nevertheless, our finding that Fetuin-A is significantly
upregulated in a majority of ADPKD patients and in
mouse kidneys deficient in Pkd1 or one of its down-
stream targets might become clinically useful to aid in
diagnosis.
Conclusions
In summary, our findings demonstrate that Fetuin-A
production is upregulated in cystic kidneys of two dif-
ferent mouse models of ADPKD and excreted in the
urine. In ADPKD patients, urinary Fetuin-A levels were
significantly elevated, with a close correlation between
fetuinuria and disease progression. While the precise
mechanisms underlying the increase of Fetuin-A secre-
tion in the kidney and its role in cystic disease remain
to be determined, our findings establish urine Fetuin-A
as a novel biomarker of the progression of ADPKD in
humans. Further studies are warranted to examine the
pathogenic mechanisms of elevated Fetuin-A and its
role in the diagnosis of ADPKD.
Figure 3 Evaluation of Fetuin-A as a biomarker for ADPKD. (a) ELISA quantification of Fetuin-A levels normalized to creatinine in urine of
ADPKD (n = 66), healthy volunteers (n = 17) and control patients with various renal diseases (n = 50). Solid lines indicate mean. (b) Evolution of
urinary levels of Fetuin-A normalized to creatinine during 5 visits (V) every 6 months in 19 early ADPKD patients. Average relative change (Δ, %)
and p-values are indicated. (c) Urinary levels of Fetuin-A normalized to creatinine stratified by CKD stages evaluated based on eGFR values. Stage
1, eGFR = 115 ± 10 ml/min/1.73 m2 (range, 96–129), n = 23; stage 2, eGFR = 77 ± 8 ml/min/1.73 m2 (range, 61–89), n = 15; stage 3, eGFR = 45 ±
9 ml/min/1.73 m2 (range, 31–59), n = 16; stage 4, eGFR = 21 ± 2 ml/min/1.73 m2 (range, 18–25), n = 7 and stage 5, eGFR = 11 ± 1 ml/min/1.73 m2
(range, 10–14), n = 5. Solid lines indicate mean. Significance was calculated by one-way ANOVA (p = 0.023).
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Table 2 Levels of urinary Fetuin-A correlate with ADPKD progression
Early ADPKD V0 V1 V2 V3 V4
Time (months) 0 6 12 18 24
Cases (n) 19 19 19 19 19
Fetuin-A [μg/L]* 71.6 ± 43.7 95.6 ± 47.8 114.3 ± 65.3 136.1 ± 56.7 150.7 ± 66.4
p-value n.s. n.s. n.s. 0.014 0.0001
Fetuin-A [μg/mmol creatinine]* 13.9 ± 9.6 17.1 ± 13.8 19.6 ± 14.6 24.3 ± 16.3 27.7 ± 16.7
p-value n.s. n.s. n.s. 0.021 0.003
*Data are presented as mean ± SD. One-way ANOVA followed by Bonferroni’s test was used for comparison (p < 0.05) for both Fetuin-A and Fetuin-A/Creatinine
ratio. n.s., not significant.
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Mice and mutant alleles
Mice heterozygous for a targeted null allele of Bicc1 [29]
were maintained on a C57BL/6 genetic background in
individually ventilated cages at the EPFL animal facility.
To induce a kidney-specific deletion of Pkd1, tam-
KspCad-CreERT2; Pkd1lox2–11/lox2–11 mice orally received
tamoxifen by gavage as described [23]. For early stage of
cyst formation, mice were sacrificed 3 weeks after admin-
istration of 0.5 mg taxomifen at postnatal days 10–12. For
late stage of cyst formation, mice were sacrificed 9 weeks
after administration of 0.5 mg taxomifen at postnatal days
10–12. All animal experiments were approved by the
Animal Care and Use Committee of Leiden University
and by the Commission for Biotechnology in Animals
of the Dutch Ministry of Agriculture, or by the Veterinary
Service of the Swiss canton of Vaud.
Clinical specimen collection
133 participants (66 ADPKD and 50 patients with
various renal diseases and 17 normal volunteers) were
enrolled in the ADPKD cohort of the division of
Nephrology of the Lausanne University Hospital (CHUV)
(Lausanne, Switzerland) prospectively between 2009 and
2014. Clinical data of all participants were collected. All
patients were informed about the purpose of the study
and gave their informed consent. This study was approved
by the local research ethical board and conducted in
accordance with the ethical standards of the Helsinki
Declaration.Table 3 Correlation between levels of urinary Fetuin-A and C
CKD stage 1 2
Cases (n) 23 15
Fetuin-A [μg/L]* 88.4 ± 42.4 90.6 ± 51.5
p-value n.s.
Fetuin-A [μg/mmol creatinine]* 13.4 ± 11.1 14.5 ± 8.8
p-value n.s.
*Data are presented as mean ± SD. n.s., not significant.
The 66 ADPKD patients were stratified by CKD stages (1 to 5). The stages are based
Bonferroni’s test was used for comparison (p < 0.05) for both Fetuin-A and Fetuin-A/Biochemical assays
Each human urine sample was directly collected into
sterile plastic tube and then stored at −80°C for further
analysis. Blood samples were immediately processed.
Serum creatinine, osmolality, sodium, potassium, cal-
cium, phosphate, BUN, uric acid and urine creatinine,
osmolality, sodium, potassium, total proteins were mea-
sured at the central lab of the Lausanne University Hos-
pital (Lausanne, Switzerland). Serum creatinine values
were used to calculate estimated glomerular filtration
rate (eGFR) using the CKD-Epidemiology Collaboration
(CKD-EPI) equation [49].
RNA isolation, library preparation and Affymetrix cDNA
microarray hybridization
Kidney RNA was extracted using Trizol (Invitrogen)
according to the manufacturer instructions. RNA concen-
tration and purity were determined using a Nanodrop
(Thermo Fisher, Waltham, MA). RNA integrity was as-
sessed on a Bioanalyzer (Agilent, Santa Clara, CA). High-
quality RNA samples (RNA Integrity Number ≥ 8) were
used for library preparation.
Indirect immunofluorescent labelling
Postnatal mouse kidneys were fixed in 4% paraformalde-
hyde in PBS for 1.5 hrs, rinsed with PBS, and soaked in
15% sucrose over night at 4°C and embedded in
Optimum Cutting Temperature (OCT) compound on dry
ice. Cryosections (8 μM) were permeabilised for 10 min
with 0.2% Triton X-100 in PBS, blocked with PBSKD stage of patients
3 4 5
16 7 5
113.1 ± 63.7 152.1 ± 64.8 172.4 ± 22.8
0.024 0.003 0.0001
19.4 ± 12.9 25.1 ± 13.6 30.2 ± 19.3
0.041 0.027 0.012
on estimated glomerular filtration rate (eGFR). One-way ANOVA followed by
creatinine ratio.
Figure 4 Receiver Operating Characteristic (ROC) curves of urinary Fetuin-A as a biomarker for detection of ADPKD. Receiver Operation
Characteristic (ROC) curves. The area under the ROC curve was 0.74 (95% CI, 0.6397 to 0.8505, p < 0.05) for ADPKD diagnosis, 0.67 (95% CI, 0.5276
to 0.8143, p < 0.05) for early ADPKD diagnosis, 0.87 (95% CI, 0.7720 to 0.9692, p < 0.05) for advanced ADPKD diagnosis.
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kit (Vector labs, #SP-2002). Biotinylated LTL (Vector labs,
B-1325), 1:200, and goat anti-Fetuin-A antibody (1:300)
were added over night at 4°C. Secondary antibody (anti-
rabbit Alexa 488, Molecular Probes) and streptavidin
pacific blue (Lifetechnologies) were incubated for 1 hr
at 25°C at 1:800 and 1:400, respectively, in PBS con-
taining 0.1% Triton X-100. Images were acquired with a
20× objective on a Leica LSM700 confocal microscope.
Western blot analysis
Frozen kidneys were directly lysed in Laemmli buffer by
ultrasonication on ice and centrifuged to remove debris
while retaining cyst fluids [45] and urine. For Western
blot analysis, urine samples were centrifuged at 3,500 × g
for 5 min at 4°C. Proteins were separated by electrophoresis
on a 7.5% sodium dodecyl sulfate-polyacrylamide gel and
transferred onto nitrocellulose membranes (Amersham-
Biosciences). The membranes were blocked for 1 h at 37°C
in a solution of PBS containing 5% non-fat milk powder
and 0.05% Tween-20 (PBS-T) and then incubated over-
night at 4°C with goat polyclonal primary antibody against
Fetuin-A (diluted 1:200; Santa Cruz Biotechnology
Inc., USA) or mouse anti-γ-tubulin (diluted 1:1000;
Sigma). Membranes were washed three times for
10 min in PBS-T and then incubated with the secondary
antibodies peroxidase-conjugated anti-mouse or anti-
rabbit (GE Healthcare) and anti-goat antibodies (Santa
Cruz Biotechnology Inc., USA) at room temperature for
1 h. The proteins were detected using an enhanced chemi-
luminescence detection system (ECL-Direct systems
RPN3000; Pierce Biotechnology, Inc., Rockford, IL, USA).
Densitometric analysis of immunoblots and normalization
to γ-tubulin expression was performed using Image J
software.Enzyme-linked immunosorbent assay (ELISA)
Urine samples were centrifuged at 3,500 × g for 5 min at
4°C to remove debris prior to ELISA analysis. The concen-
trations of Fetuin-A in the urine samples were measured
with a Fetuin-A (AHSG) Human ELISA kit (Abcam,
Cambridge, UK). The assay was performed according
to the instructions recommended by the manufacturer.
The standard curve was created using lyophilized human
Fetuin-A standard preparation supplied with the assay.
Following the colorimetric reaction, the optical density
was read at 450 nm using a spectrophotometer, and con-
verted to concentrations in μg/L. Urine creatinine levels
were measured at the central lab of the Lausanne University
hospital using a Cobas-Mira analyzer (Roche). The levels
of Fetuin-A were normalized according to urine creatinine
concentrations (Fetuin-A: μg/mmol creatinine). Every sam-
ple was tested in duplicate.
Statistical analysis
All data were collected and presented as mean ± stand-
ard deviation. Normal distribution of the data was
assessed using Shapiro-Wilk test. Differences among two
groups were compared by unpaired Student’s t-test. For
comparison among multiple experimental conditions, a
nonparametric one-way analysis of variance (ANOVA)
followed by Bonferroni’s test for multiple comparisons
was used. P < 0.05 was considered a statistically signifi-
cant difference. Receiving operating curve (ROC) ana-
lyses were used to explore the diagnostic performance of
urinary Fetuin-A (μg/mmol creatinine) over a range of
possible clinical conditions. The best statistical cut-off
value of Fetuin-A (μg/mmol creatinine) was defined as
the point at which the sum of sensitivity and specificity
is more than that at other points. GraphPad Prism v6
was used.
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